β€’
Dec 31, 2021

Beauty Health Q4 2021 Earnings Report

Reported record fourth quarter and fiscal year 2021 financial results.

Key Takeaways

The Beauty Health Company reported strong Q4 2021 results with net sales increasing 105.6% compared to Q4 2020, driven by growth in the U.S., EMEA, and APAC regions. The company exceeded its guidance for the quarter and full year, navigating macro challenges and COVID-19 impacts.

Net sales increased 105.6% compared to Q4 2020, reaching $77.9 million.

Delivery Systems net sales increased to $42.7 million, with over 1,800 systems sold during the quarter.

Consumables net sales increased to $35.2 million compared to the same period last year.

Adjusted EBITDA increased to $8.5 million compared to $3.6 million in Q4 2020.

Total Revenue
$77.9M
Previous year: $37.9M
+105.6%
EPS
-$0.12
Previous year: -$0.21
-42.9%
Gross Margin
72.9%
Previous year: 60.8%
+19.9%
Adjusted EBITDA
$8.5M
Previous year: $3.6M
+136.1%
Adjusted EBITDA Margin
10.9%
Previous year: 9.4%
+16.0%
Gross Profit
$56.8M
Previous year: $23M
+146.4%
Cash and Equivalents
$902M
Previous year: $9.49M
+9407.5%
Free Cash Flow
-$3.07M
Previous year: -$1.32M
+131.7%
Total Assets
$1.22B
Previous year: $223M
+447.0%

Beauty Health

Beauty Health

Beauty Health Revenue by Segment

Beauty Health Revenue by Geographic Location

Forward Guidance

BeautyHealth is providing a fiscal 2022 net sales guidance range of $320.0 million to $330.0 million and adjusted EBITDA of approximately $50.0 million.

Positive Outlook

  • Momentum in health and wellness
  • Management's confidence in the business as the Company executes against its growth plan
  • Launch in the first half of 2022 of Syndeo, the next generation HydraFacial Delivery System
  • Wi-Fi-enabled radio frequency identification that will allow us to build a connected platform
  • Better understand consumer and provider behavior

Challenges Ahead

  • No material deterioration in general market conditions or other factors related to COVID-19 trends
  • Potential risk for further market closures or other restrictive measures from existing or new COVID-19 strains
  • Uneven global rollout and adoption of vaccines
  • Inflationary headwinds related to higher raw material, shipping and labor costs
  • Assumes a largely reopened global market, which would be negatively impacted if closures or other restrictive measures persist or are reimplemented

Revenue & Expenses

Visualization of income flow from segment revenue to net income